Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure

Circulation: Heart Failure

Volumn 5, Issue 4, 2012, Pages 484-492

  Morooka, Hanako ^a   Iwanaga, Yoshitaka ^a   Tamaki, Yodo ^b   Takase, Toru ^a   Akahoshi, Yasumitsu ^c   Nakano, Yoshimasa ^d   Fujiki, Hiroyuki ^d   Miyazaki, Shunichi ^a  

^a KINKI UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Heart failure; Kidney; Myocardium; Vasopressin type 2 receptor antagonist

Indexed keywords

AQUAPORIN 2; ATRIAL NATRIURETIC FACTOR; ENDOTHELIN 1; MESSENGER RNA; RENIN; TOLVAPTAN; VASOPRESSIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DISEASE COURSE; DRUG MEGADOSE; HEART FAILURE; HEART MUSCLE; HEART PROTECTION; HISTOPATHOLOGY; KIDNEY; KIDNEY FUNCTION; LOW DRUG DOSE; LUNG CONGESTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; RENAL PROTECTION; SURVIVAL; URINE VOLUME;

ADMINISTRATION, ORAL; ANIMALS; ARGININE VASOPRESSIN; BENZAZEPINES; BIOLOGICAL MARKERS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; HEART FAILURE; HORMONE ANTAGONISTS; HYPERTENSION; KIDNEY; KIDNEY DISEASES; MALE; MYOCARDIUM; NATRIURETIC PEPTIDES; RATS; RATS, INBRED DAHL; RECEPTORS, VASOPRESSIN; RNA, MESSENGER; SODIUM CHLORIDE, DIETARY; TIME FACTORS; URINATION; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 84864622986     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.111.965392     Document Type: Article

References (37)

1. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling: concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling, on behalf of an International Forum on Cardiac Remodeling J Am Coll Cardiol. 2000;35:569-582.
2. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341:577-585.
3. Goldsmith SR, Francis GS, Cowley AW Jr, Levine TB, Cohn JN. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol. 1983;1:1385-1390.
4. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kubo SH, Rudin-Toretsky E, Yusuf S. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD) Circulation. 1990;82:1724-1729.
5. Goldsmith SR. The role of vasopressin in congestive heart failure. Cleve Clin J Med. 2006;73:S19-S23.
6. Nielsen S, Chou CL, Marples D, Christensen EI, Kishore BK, Knepper MA. Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proc Natl Acad Sci U S A. 1995;92:1013-1017.
7. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C; SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355: 2099-2112.
8. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C.; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297:1319-1331.
9. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297:1332-1343.
10. Konstam MA, Udelson JE. Hyponatraemia and vasopressin in heart failure: markers or mediators? Eur J Heart Fail. 2011;13:242-244.
11. Bishara B, Shiekh H, Karram T, Rubinstein I, Azzam ZS, Abu-Saleh N, Nitecki S, Winaver J, Hoffman A, Abassi ZA. Effects of novel vasopressin receptor antagonists on renal function and cardiac hypertrophy in rats with experimental congestive heart failure. J Pharmacol Exp Ther. 2008;326:414-422.
12. Inoko M, Kihara Y, Morii I, Fujiwara H, Sasayama S. Transition from compensatory hypertrophy to dilated, failing left ventricles in Dahl salt-sensitive rats. Am J Physiol. 1994;267:H2471-H2482.
13. Adhikary LP, Yamamoto T, Isome M, Nakano Y, Kawasaki K, Yaoita E, Kihara I. Expression profile of extracellular matrix and its regulatory proteins during the process of interstitial fibrosis after antiglomerular basement membrane antibody-induced glomerular sclerosis in Sprague-Dawley rats. Path Int. 1999;49:716-725.
14. Shoker AS. Application of the clearance concept to hyponatremic and hypernatremic disorders: a phenomenological analysis. Clin Chem. 1994;40:1220-1227.
15. Schrier RW. Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor? J Am Coll Cardiol. 2006;47:1-8.
16. Iwanaga Y, Kihara Y, Inagaki K, Onozawa Y, Yoneda T, Kataoka K, Sasayama S. Differential effects of angiotensin II versus endothelin-1 inhibitions in hypertrophic left ventricular myocardium during transition to heart failure. Circulation. 2001;104:606-612.
17. Hupf H, Grimm D, Riegger GA, Schunkert H. Evidence for a vasopressin system in the rat heart Circ Res. 1999;84:365-370.
18. Watanabe I, Tani S, Nagao K, Anazawa T, Kawamata H, Ohguchi S, Kanmatsuse K, Kushiro T. Regulation of arginine vasopressin in the human heart. Circ J. 2005;69:1401-1404.
19. Li X, Chan TO, Myers V, Chowdhury I, Zang XQ, Song J, Zhang J, Andrel J, Funakoshi H, Robbins J, Koch WJ, Hyslop T, Cheung JY, Feldman AM. Controlled and cardiac-restricted overexpression of the arginine vasopressin V1a receptor causes reversible left ventricular dysfunction through G?q-mediated cell signaling. Circulation. 2011;124:572-581.
20. Gheorghiade M, Gattis WA, O'Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C; Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963-1971.
21. Cosrello-Boerrigter LC, Smith WB, Boerrigter G, Ouyang J, Zimmer CA, Orlandi C, Burnett JC. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol. 2006;290:F273-F278.
22. Veeraveedu PT, Watanabe K, Ma M, Palaniyandi SS, Yamaguchi K, Kodama M, Aizawa Y. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure. Biochem Pharmacol. 2008;75:1322-1330.
23. Burrell LM, Phillips PA, Risvanis J, Chan RK, Aldred KL, Johnston CI. Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat. Am J Physiol. 1998;275:H176-H182.
24. Costello-Boerrigter LC, Boerrigter G, Cataliotti A, Harty GJ, Burnett JC Jr. Renal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failure. Circ Heart Fail. 2010;3:412-419.
25. Kramer BK, Schweda F, Riegger GA. Diuretic treatment and diuretic resistance in heart failure. Am J Med. 1999;106:90-96.
26. Xu DL, Martin PY, Ohara M, St John J, Pattison T, Meng X, Morris K, Kim JK, Schrier RW. Upregulation of aquaporin-2 water channel expression in chronic heart failure rat. J Clin Invest. 1997;99:1500-1505.
27. Christensen BM, Marples D, Jensen UB, Frokiaer J, Sheikh-Hamad D, Knepper M, Nielsen S. Acute effects of vasopressin V2-receptor antagonist on kidney AQP2 expression and subcellular distribution. Am J Physiol. 1998;275:F285-F297.
28. Onozato ML, Tojo A, Kobayashi N, Goto A, Mathuoka H, Fujita M. Dual blockade of aldosterone and angiotensin II additively suppresses TGF-b and NADPH oxidase in the hypertensive kidney. Nephrol Dial Transplant. 2007;22:1314-1322.
29. Wong NL, Tsui JK. Upregulation of vasopressin V2 and aquaporin 2 in the inner medullary collection duct of cardiomyopathic hamsters is attenuated by enalapril treatment. Metabolism. 2002;51:970-975.
30. Lütken SC, Kim SW, Jonassen T, Marples D, Knepper MA, Kwon TH, Frkiaer J, Nielsen S. Changes of renal AQP2, ENaC, and NHE3 in experimentally induced heart failure: response to angiotensin II AT1 receptor blockade Am J Physiol Renal Physiol. 2009;297:F1678-F1688.
31. Carmosino M, Brooks HL, Cai Q, Davis LS, Opalenik S, Hao C, Breyer MD. Axial heterogeneity of vasopressin-receptor subtypes along the human and mouse collecting duct. Am J Physiol Renal Physiol. 2007;292:F351-F360.
32. Bardoux P, Bruneval P, Heudes D, Bouby N, Bankir L. Diabetes-induced albuminuria: role of antidiuretic hormone as revealed by chronic V2 receptor antagonism in rats. Nephrol Dial Transplant. 2003;18:1755-1763.
33. Okada T, Sakaguchi T, Hatamura I, Saji F, Negi S, Otami H, Muragaki Y, Kawachi H, Shigematsu T. Tolvaptan, a selective oral vasopressin V2 receptor antagonist, ameliorates podocyte injury in puromycin aminonucleoside nephrotic rats. Clin Exp Nephrol. 2009;13:438-446.
34. Gattone VH, Maser RL, Tian C, Rosenberg JM, Branden MG. Developmental expression of urine concentration associated genes and their altered expression in murine infantile type polycystic kidney disease. Dev Genet. 1999;24:309-318.
35. Torres VE, Meijer E, Bae KT, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang JJ, Czerwiec FS. Rationale and Design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) 3-4 Study. Am J Kidney Dis. 2011;57: 692-699.
36. Alonso G, Galibert E, Boulay V, Guillou A, Jean A, Compan V, Guillon G. Sustained elevated levels of circulation vasopressin selectively stimulate the proliferation of kidney tubular cells via the activation of V2 receptors. Endocrinology. 2009;150:239-250.
37. Morii I, Kihara Y, Inoko M, Sasayama S. Myocardial contractile efficiency and oxygen cost of contractility are preserved during transition from compensated hypertrophy to failure in rats with salt-sensitive hypertension. Hypertension. 1998;31:949-960.